160 Health International Limited (stock code: 02656) issued a voluntary business update announcing the progressive deployment of its AI-enabled “Medical Digital Staff” system across medical institutions. Built on the Group’s “Platform + AI Agent + Operation” model, the initiative integrates proprietary agents—exemplified by OpenClaw—throughout pre-consultation, consultation and post-consultation workflows.

Key functions include multi-agent patient management, health education, automated medical-record generation, intelligent insurance calculation and departmental ledger management, all designed to reduce administrative workloads and free clinicians to focus on core medical duties.

Internally, AI agents have been embedded in product R&D, content production and customer service. Management reports a product iteration cycle reduction of more than 60%, alongside faster deployment and delivery for external medical partners following the full rollout of OpenClaw.

The Group emphasizes a “security-first” approach, applying end-to-end security hardening to all AI agents via its in-house technical team to safeguard system stability. Leveraging authentic doctor-patient interaction scenarios and established platform operations, 160 Health intends to continue refining advanced AI applications in healthcare to create long-term value for shareholders.